Clinical Trial

Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab

Study acronym: CAPT-02
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2023 (before its estimated January 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of irinotecan liposomes with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin (LV) with or without adelizumab for resectable pancreatic cancer by assessing the 12-month EFS rate
Trial Details
NCT Number NCT06172036
Lead Sponsor Zhejiang University
Conditions Neoadjuvant Chemotherapy, Resectable Pancreatic Cancer
Enrollment 180 participants
Start Date 2024-01-20
Primary Completion 2026-01-20 (estimated)
Study Completion 2027-01-20 (estimated)
Updated on ClinicalTrials.gov 2023-12-15